BIO-TECHNE CEO acquires 21,736 shares in equity awards

Q: How many TECH shares did Kim Kelderman acquire?

Kim Kelderman acquired 21,736 shares of BIO-TECHNE common stock on August 15, 2026.

Q: How many shares did the TECH CEO deliver or withhold?

Kim Kelderman reported 10,955 common shares delivered or withheld for payment of exercise price or tax liability on August 15, 2026, at $72.40 per share.

Restricted stock units are also scheduled to vest on August 15, 2027 and August 15, 2028, alongside 2026 vesting and forfeitures of remaining performance awards.

Available on EDGAR 11/02/2026 - 04:36 PM EST Accepted by SEC EDGAR 11/02/2026 - 04:35 PM EST

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

4/A

Rhea-AI Filing Summary

BIO-TECHNE Corp (TECH) CEO Kim Kelderman reported equity-award transactions on August 15, 2026, including acquisition of 21,736 common shares and 10,955 shares delivered or withheld for payment of exercise price or tax liability at $72.40 per share. The report lists dispositions to the issuer of 22,044 and 23,949 performance stock options and 8,190 and 8,698 performance restricted stock units. The board authorized discretionary vesting of 1,837 and 1,996 performance options and 683 and 725 performance restricted stock units; the remainder of those performance awards was forfeited. Other restricted stock units vested on August 15, 2026, with additional vesting scheduled for August 15, 2027 and August 15, 2028.

Insider Trade Summary

21,736 shares exercised/converted

Exercise 10 txns

Insider Kelderman Kim

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Disposition	Performance Stock Options (Right to Buy) ^F1	22,044	$0.00	$0.00
Disposition	Performance Stock Options (Right to Buy) ^F2	23,949	$0.00	$0.00
Exercise	Performance Restricted Stock Units ^{F3, F4}	683	$0.00	$0.00
Disposition	Performance Restricted Stock Units ^{F3, F4}	8,190	$0.00	$0.00
Exercise	Performance Restricted Stock Units ^{F3, F5}	725	$0.00	$0.00
Disposition	Performance Restricted Stock Units ^{F3, F5}	8,698	$0.00	$0.00
Exercise	Restricted Stock Units ^{F3, F6}	8,543	$0.00	$0.00
Exercise	Restricted Stock Units ^{F3, F7}	11,785	$0.00	$0.00
Exercise	Common Stock	21,736	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	10,955	$72.40	$793K

Holdings After Transaction: Performance Stock Options (Right to Buy) — 3,833 contracts (Direct); Performance Restricted Stock Units — 0 contracts (Direct); Restricted Stock Units — 32,113 contracts (Direct); Common Stock — 82,894 shares (Direct)

Footnotes (7)

F1. On 8/15/2026, the Board of Directors authorized discretionary vesting for 1,837 performance options. The remainder of the performance options were forfeited.
F2. On 8/15/2026, the Board of Directors authorized discretionary vesting for 1,996 performance options. The remainder of the performance options were forfeited.
F3. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
F4. On 8/15/2026, the Board of Directors authorized discretionary vesting for 683 performance RSUs. The remainder of the performance RSUs were forfeited.
F5. On 8/15/2026, the Board of Directors authorized discretionary vesting for 725 performance RSUs. The remainder of the performance RSUs were forfeited.
F6. 8,543 restricted stock units vest on 8/15/2026, and 8,544 restricted stock units vest on 8/15/2027.
F7. 11,785 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 11,784 restricted stock units vest on 8/15/2028.

Key Figures

Common shares acquired: 21,736 shares Shares delivered or withheld: 10,955 shares Reported per-share price: $72.40 per share +5 more

8 metrics

Common shares acquired 21,736 shares August 15, 2026

Shares delivered or withheld 10,955 shares For payment of exercise price or tax liability on August 15, 2026

Reported per-share price $72.40 per share Shares delivered or withheld on August 15, 2026

Performance stock options disposed to issuer 22,044 options August 15, 2026

Performance stock options disposed to issuer 23,949 options August 15, 2026

Performance restricted stock units disposed to issuer 8,190 units August 15, 2026

Performance restricted stock units disposed to issuer 8,698 units August 15, 2026

Performance restricted stock units authorized for discretionary vesting 683 units and 725 units August 15, 2026

Key Terms

Performance Stock Options (Right to Buy), Performance Restricted Stock Units, contingent right

3 terms

Performance Stock Options (Right to Buy) technical

"Performance Stock Options (Right to Buy)"

Performance Restricted Stock Units technical

"Performance Restricted Stock Units"

Performance restricted stock units (PRSUs) are promises to deliver company shares to employees or executives only if the business meets specific performance targets and any time-based holding rules. Think of them as a bonus that converts into stock only after set goals are reached, so investors watch PRSUs for two reasons: they can dilute existing shares if paid out, and they signal how closely management’s pay is tied to company performance.

contingent right technical

"Each restricted stock unit represents a contingent right to receive one share"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many TECH shares did Kim Kelderman acquire?

Kim Kelderman acquired 21,736 shares of BIO-TECHNE common stock on August 15, 2026.

How many shares did the TECH CEO deliver or withhold?

Kim Kelderman reported 10,955 common shares delivered or withheld for payment of exercise price or tax liability on August 15, 2026, at $72.40 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kelderman Kim

(Last)

(First)

(Middle)

614 MCKINLEY PLACE NE

(Street)

MINNEAPOLIS

MINNESOTA

55413

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIO-TECHNE Corp [ TECH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
08/18/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/15/2026		M		21,736	A	$0	93,849	D
Common Stock	08/15/2026		F		10,955	D	$72.4	82,894	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Performance Stock Options (Right to Buy)	$84.61	08/15/2026		D			22,044	⁽¹⁾	⁽¹⁾	Common Stock	22,044	$0	1,837	D
Performance Stock Options (Right to Buy)	$68.54	08/15/2026		D			23,949	⁽²⁾	⁽²⁾	Common Stock	23,949	$0	1,996	D
Performance Restricted Stock Units	⁽³⁾	08/15/2026		M			683	⁽⁴⁾	⁽⁴⁾	Common Stock	683	$0	8,190	D
Performance Restricted Stock Units	⁽³⁾	08/15/2026		D			8,190	⁽⁴⁾	⁽⁴⁾	Common Stock	8,190	$0	0	D
Performance Restricted Stock Units	⁽³⁾	08/15/2026		M			725	⁽⁵⁾	⁽⁵⁾	Common Stock	725	$0	8,698	D
Performance Restricted Stock Units	⁽³⁾	08/15/2026		D			8,698	⁽⁵⁾	⁽⁵⁾	Common Stock	8,698	$0	0	D
Restricted Stock Units	⁽³⁾	08/15/2026		M			8,543	⁽⁶⁾	⁽⁶⁾	Common Stock	8,543	$0	8,544	D
Restricted Stock Units	⁽³⁾	08/15/2026		M			11,785	⁽⁷⁾	⁽⁷⁾	Common Stock	11,785	$0	23,569	D

Explanation of Responses:

1. On 8/15/2026, the Board of Directors authorized discretionary vesting for 1,837 performance options. The remainder of the performance options were forfeited.

2. On 8/15/2026, the Board of Directors authorized discretionary vesting for 1,996 performance options. The remainder of the performance options were forfeited.

3. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.

4. On 8/15/2026, the Board of Directors authorized discretionary vesting for 683 performance RSUs. The remainder of the performance RSUs were forfeited.

5. On 8/15/2026, the Board of Directors authorized discretionary vesting for 725 performance RSUs. The remainder of the performance RSUs were forfeited.

6. 8,543 restricted stock units vest on 8/15/2026, and 8,544 restricted stock units vest on 8/15/2027.

7. 11,785 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 11,784 restricted stock units vest on 8/15/2028.

	/s/ Andrew Nick, Attorney-in-Fact for Kim Kelderman pursuant to Power of Attorney previously filed.	11/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR